NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation29-05-2024
29-05-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Earnings call Audio Recording29-05-2024
Natco Pharma Q4 Results Review - Beat On Earnings: Dolat Capital
Complex and niche products to drive export growth29-05-2024
Q4FY24 Quarterly Result Announced for Natco Pharma Ltd.
Pharmaceuticals company Natco Pharma announced Q4FY24 & FY24 results: Q4FY24: Total Revenue stood at Rs 11,103 million Pharma Export Formulations at Rs 9,549 million Consolidated Total Revenue for FY24 stood at Rs 41,269 million Earnings Before Interest Tax Depreciation and Amortization stood at Rs 5,393 million for Q4FY24 and Rs 18,795 million for FY24 EBITDA Margin for Q4FY24 & FY24 was at 48.6% and 45.5% respectively Profit Before Tax for Q4FY24 at Rs 4,776 million and Rs 16,735 million for FY24 Basic and Diluted EPS for FY24 is Rs 77.34 per share Profit after tax for Q4FY24 was at Rs 3,863 million Net Profit for FY24 was at Rs 13,883 million EBITDA and EBITDA Margin includes other income Investment of USD 2 million in Cellogen Therapeutics Private Ltd., with R&D; programs involving Cell and Gene Therapy Solutions Result PDF28-05-2024
Natco Pharma Results Earnings Call for Q4FY24
Conference Call with Natco Pharma Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.28-05-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of News Paper Publication of the Audited Financial Results of the Company for the Quarter and Year ended March 31, 202428-05-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investors Presentation on the Audited Financial Results for the quarter and year ended 31st Match, 202428-05-2024
Natco Pharma Shares Soar To Three-Month High As Q4 Profit Beats Estimates
The stock rose as much as 6.86% during the day to Rs 1,100 apiece on the NSE.28-05-2024
NATCO PHARMA LTD. - 524816 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31st March, 202427-05-2024
NATCO PHARMA LTD. - 524816 - Audited Financial Results For The Quarter And Year Ended 31St March, 2024
Audited Financial Results for the quarter and year ended 31st March, 202427-05-2024